An Avidity-Based PD-L1 Antagonist Using Nanoparticle-Antibody Conjugates for Enhanced Immunotherapy-Reference-Cited by-同舟云学术

An Avidity-Based PD-L1 Antagonist Using Nanoparticle-Antibody Conjugates for Enhanced Immunotherapy

Published:2020-06-08 Issue:7 Volume:20 Page:4901-4909
ISSN:1530-6984
Container-title:Nano Letters
language:en
Short-container-title:Nano Lett.

Author:

Bu Jiyoon¹,Nair Ashita¹,Iida Mari²,Jeong Woo-jin¹^ORCID,Poellmann Michael J.¹^ORCID,Mudd Kara¹,Kubiatowicz Luke J.¹,Liu Elizabeth W.¹,Wheeler Deric L.²³,Hong Seungpyo¹³⁴^ORCID

Affiliation:

1. Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States

2. Department of Human Oncology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States

3. Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States

4. Yonsei Frontier Lab and Department of Pharmacy, Yonsei University, Seoul 03722, Republic of Korea

Funder

National Cancer Institute

National Institute of Dental and Craniofacial Research

Division of Materials Research

Publisher

American Chemical Society (ACS)

Subject

Mechanical Engineering,Condensed Matter Physics,General Materials Science,General Chemistry,Bioengineering

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.nanolett.0c00953

Reference49 articles.

1. Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention

2. Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?

3. PD-1 and Its Ligands in Tolerance and Immunity

4. PD-L1: PD-1 Interaction Contributes to the Functional Suppression of T-Cell Responses to Human Uveal Melanoma Cells In Vitro

5. PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current advance of nanotechnology in diagnosis and treatment for malignant tumors;Signal Transduction and Targeted Therapy;2024-08-12

2. Enhancing cancer immunotherapy: Exploring strategies to target the PD-1/PD-L1 axis and analyzing the associated patent, regulatory, and clinical trial landscape;European Journal of Pharmaceutics and Biopharmaceutics;2024-07

3. Clinical applications and perspectives of immune checkpoint inhibitors in oral squamous cell carcinoma;Oncologie;2024-06-11

4. Polymer-based antibody mimetics (iBodies) target human PD-L1 and function as a potent immune checkpoint blocker;Journal of Biological Chemistry;2024-06

5. On the uncertainty of the correlation between nanoparticle avidity and biodistribution;European Journal of Pharmaceutics and Biopharmaceutics;2024-05